Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003624 · ClinicalTrials.gov registry record · Phase 2
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00003624: Clinical Trial Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00003624 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003624, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of amifostine in reducing the risk of side effects caused by cisplatin and paclitaxel in treating women who have ovarian, peritoneal, cervical, fallopian tube, uterine, or endometrial cancer.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-12 |
| Phase | Phase 2 |
Why NCT00003624 stopped before completion
NCT00003624 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00003624 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003624 about?
NCT00003624 is a clinical study titled "Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of amifostine in redu...
What is the current status of trial NCT00003624?
This trial is currently terminated. It is a Phase 2 study. The study started on 1998-12.
What interventions are being tested in trial NCT00003624?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003624?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia